<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741659</url>
  </required_header>
  <id_info>
    <org_study_id>691/2020/Sper/AOUBo</org_study_id>
    <nct_id>NCT04741659</nct_id>
  </id_info>
  <brief_title>Tidal Volume in Patients With &quot;de Novo&quot; Acute Hypoxemic Respiratory Failure</brief_title>
  <acronym>DENOVT</acronym>
  <official_title>Tidal Volume in Patients With &quot;de Novo&quot; Acute Hypoxemic Respiratory Failure Receiving Non-invasive Respiratory Supports: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protective ventilation can be difficult to achieve during noninvasive ventilation for &quot;de&#xD;
      novo&quot;acute hypoxemic respiratory failure (i.e., not due to exacerbation of chronic lung&#xD;
      disease or cardiac failure).Recent data suggest patient self-inflicted lung injury (P-SILI)&#xD;
      as a possible mechanism aggravating lung damage in these patients.&#xD;
&#xD;
      The aim of this study is evaluate the tidal volume, measured by respiratory inductance&#xD;
      plethysmography, in patients receiving different non invasive respiratory support.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory pattern</measure>
    <time_frame>30 minutes</time_frame>
    <description>the way the patient is breathing recorded by respiratory inductance plethysmography (RIP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>respiratory mechanics</measure>
    <time_frame>30 minutes</time_frame>
    <description>the inspiratory effort of the patient recorded by esophageal pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in Arterial Blood Gases (ABGs)</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Arterial Blood Gases, namely arterial oxygen (PaO2) and carbon dioxyde (PaCO2) tension will be analyzed from a sample taken from the arterial artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Dyspnea will be recorded using the Borg scale that is a numeric scale where 0 is no dyspnea and 10 the maximal dyspnea that a patient can imagine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort score</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>this will be assessed using a dedicated visual analog scale (VAS with a length of 20 cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (BP) and Heart rate (HR) measurements</measure>
    <time_frame>30 minutes</time_frame>
    <description>blood pressure and heart rate will be assessed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Acute Hypoxemic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>spontaneous breathing trial</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the patients will be asked to breathe spontaneously using their actual low oxygen flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Flow Nasal cannula (HFNC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be asked to breathe with HFNC of 40 L/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will be asked to breathe with the Helmet CPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Invasive Ventilation (NIV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ventimask</intervention_name>
    <description>The patients will be asked to breathe spontaneously using their actual low oxygen flow</description>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_label>High Flow Nasal cannula (HFNC)</arm_group_label>
    <arm_group_label>Non Invasive Ventilation (NIV)</arm_group_label>
    <arm_group_label>spontaneous breathing trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Flow Nasal cannula (HFNC)</intervention_name>
    <description>The patients will be asked to breathe using high flow nasal cannula (HFNC). Air flow will set up to 60 l/m, temperature according to patient's comfort and FiO2 in order to obtain SpO2 values &gt;/= 92%</description>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_label>High Flow Nasal cannula (HFNC)</arm_group_label>
    <arm_group_label>Non Invasive Ventilation (NIV)</arm_group_label>
    <arm_group_label>spontaneous breathing trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Helmet CPAP</intervention_name>
    <description>The patients will be asked to breathe with Helmet. CPAP will set at 10 cmH2O and FiO2 in order to obtain SpO2 values &gt;/= 92%</description>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_label>High Flow Nasal cannula (HFNC)</arm_group_label>
    <arm_group_label>Non Invasive Ventilation (NIV)</arm_group_label>
    <arm_group_label>spontaneous breathing trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non Invasive Ventilation (NIV)</intervention_name>
    <description>the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface</description>
    <arm_group_label>Helmet CPAP</arm_group_label>
    <arm_group_label>High Flow Nasal cannula (HFNC)</arm_group_label>
    <arm_group_label>Non Invasive Ventilation (NIV)</arm_group_label>
    <arm_group_label>spontaneous breathing trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute Respiratory Failure (ARF) ( 100 &lt;PaO2/FiO2 &lt;300) due to Covid-19 infection&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Enrollment within the first 24 hours after ARF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical, radiological or istological evidence of chronic pulmonary disease.&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 30 kg/m2;&#xD;
&#xD;
          -  Previous diagnosis of Obstructive sleep apnea syndrome (OSAS)&#xD;
&#xD;
          -  Chest wall disease&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Severe hemodynamic instability ( need for amine support)&#xD;
&#xD;
          -  Acute coronary syndrome (ACS)&#xD;
&#xD;
          -  Severe arrhythmia&#xD;
&#xD;
          -  Patients unable to protect respiratory airways&#xD;
&#xD;
          -  Respiratory arrest and need for endotracheal intubation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Need for sedation&#xD;
&#xD;
          -  Home long-term oxygen therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Nava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alma Mater Studiorum University of Bologna (IT)- Director of Respiratory and Critical Care Unit/ IRCSS S.Orsola-Malpighi University Hospital, Bologna (IT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Policlinico di Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>dr. Stefano Nava</investigator_full_name>
    <investigator_title>Stefano Nava, Professor of Respiratory Medicine/ Alma Mater Studiorum University of Bologna (IT)- Director of Respiratory and Critical Care Unit/ S.Orsola-Malpighi University Hospital, Bologna (IT)</investigator_title>
  </responsible_party>
  <keyword>De novo</keyword>
  <keyword>ARF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

